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Abstract  This  research  evaluated  the  inter-batch  variability  in  the  identiﬁcation  and  quality
control of  glucose,  according  to  international  speciﬁcations  detailed  in  the  guide  CLSI  EP-15.
Type of  qualitative  research,  analytical,  not  experimental,  prospective  cross-sectional  con-
ducted at  the  Department  of  Clinical  Laboratory  at  Polyclinic  ‘‘La  Fe’’  during  January  2015  was
performed.  The  inter-batch  variability  for  glucose  in  the  semi-automated  biochemical  analyzer
URIT-810  with  liquid  enzyme  glucose-LS  reagent  (GOD-PAP)  Valtek®  batch  140825  was  evalu-
ated. The  calibrators  (CS)  were  the  lot  CS-A:  140  428,  CS-B:  120912  and  CS-C:  131  202.  Data
analysis was  performed  in  SPSS  version  20.0  statistical  analyzer  and  Microsoft  Ofﬁce  Excel  2010
for Windows.  The  values  found  by  calculating  the  sigma  metric  were:  2  (SE  −0.35),  0  (SE
1.65) −0.9  (SE  −0.75)  to  CS-A,  CS-B  and  CS-C,  respectively  (p  <  0.05).  Only  CS-A  might  be
able to  improve  their  performance,  although  with  greater  cost.  Sub-optimal  performance  char-
acteristics  by  using  standard  calibrators  show  high  inter-lot  variability,  suggesting  the  choice
and search  for  a  new  and  better  calibration  method  to  ensure  results  that  contain  no  medically
important  errors  affecting  patient  health.
© 2016  Universidad  Auto´noma  de  Nuevo  Leo´n.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Glucose  is  the  main  energetic  biomolecule  for  most  liv-
ing  systems,  responsible  for  maintaining  cellular  functions∗ Corresponding author at: Paciﬁco 957 Urb, San Felipe Lima 07,
Peru. Tel.: +51 1 4873 681; mobile: +51 1 986014954.
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4hrough  glucid  catabolism.  Since  its  isolation  in  1747  by
ndreas  Sigismund,  and  the  discovery  of  its  conﬁguration
n  1902  by  Emil  Fisher,  the  function  of  glucose  has  been
xplained  and  correlated  with  the  development  of  diverse
isorders  and  homeostatic  mechanisms  for  its  control.1
hus,  glucose  allows  for  the  diagnosis  of  several  disorders,
uch  as  diabetes  mellitus,  Cushing’s  syndrome,  meningeal
nﬂammatory  processes,  metabolic  syndrome,  heredofamil-
al  intracorpuscular  hemolysis,  and  even  enzymopathies,
ntolerance  or  improper  carbohydrate  enteric  absorption,
asson Doyma Me´xico S.A. This is an open access article under the
.0/).
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idney  diseases,  and  in  vitro  tests  for  cellular  functional
tatus  evaluation,  in  addition  to  being  used  as  a  preserva-
ion  agent  for  haemocomponents,  among  others.2 Hence,
lucose  is  transcendental  for  diagnosis  in  almost  all  clinical
aboratories  areas.
It  is  mainly  used  for  diagnosing  diabetes  mellitus  (DM),
 metabolic  disease  which  imposes  a  high  economic  and
ocial  cost  in  the  world  today,  especially  type  II  DM.
iagnosis  is  made  through  signs  and  symptoms  and  stim-
li/response  tests,  such  as  the  oral  glucose  tolerance
est  (OGTT),  among  others.3,4 Moreover,  explorations  of
arbohydrate  metabolism  are  employed,  such  as  random
lycemias,  fasting  plasmatic  glycemias,  the  glucose  toler-
nce  with  corticoids  test  and,  recently,  with  the  glycated
emoglobin  A1C  test,  as  well  as  plasmatic  insulin  level  eval-
ations,  peptide  C  and  glucagon  dosing,  and  glucose  in  urine
nd  lipid  proﬁles.5--7
Determined  values  indicate  how  the  organism  controls
lucose.  Biochemical  determination  is  generally  performed
ith  reducing  methods,  enzymatic  methods  (hexokinase,
lucose-oxidase,  and  glucose-dehydrogenase),  and  commer-
ial  determinations  by  dry  chemistry  for  clinical  diagnosis,
s  well  as  for  in-home  monitoring  and  immunoradiometric
rials.  Enzymatic  methods  in  commercial  presentations  are
he  most  utilized,  followed  by  patient  monitoring  by  dry
hemistry,  usually  with  acceptable  sensitivity  ranges  and
rror  margins.8 Nevertheless,  glucose  is  one  of  the  metabo-
ites  which  suffers  more  pre-analytic  and  analytic  changes,
nd  one  which  presents  an  elevated  biological  intra-  and
nter-individual  variability.  However,  the  reagent  maker
ncorporates  internationally-validated  technical  speciﬁca-
ions;  due  to  different  factors,  these  cannot  be  reproduced
n  the  routine  laboratory,  thus  making  quality  control  under
ork  conditions  which  guarantee  the  quality  of  their  results
ecessary.9,10
Parameters  to  ensure  quality  in  clinical  biochemistry,  as
escribed  by  the  Clinical  Laboratory  Standards  Institute
CLSI),  include  analytical  methods  and  veriﬁcation  guides
hich  lead  to  a  correct  planning  and  choosing  of  qual-
ty  control  rules  for  continuous  monitoring  of  performance
nder  work  conditions.  Obtaining  of  these  dates  the  total
rror  of  laboratory  method  (Tea)  is  comparable  to  the  max-
mum  permissible  error  designed  from  different  sources
ike  the  Clinical  Laboratory  Improvement  Amendments  1988
CLIA’88),  biological  variability,  RCPA  regulatory  require-
ents,  etc.  Subsequently,  planning  and  method  control  as
ell  as  quality  will  show  continuous  improvement.11
Quality  veriﬁcation  of  a  method’s  analytical  character-
stics  is  applicable  to  all  kinds  of  laboratories.  In  addition
o  measurable  data  on  the  system’s  performance  (inaccu-
acy  and  bias),  quality  requirements  and  real  reference
alues  are  necessary.12 Quality  requirements  for  glucose  are
iverse,  with  maximum  quantiﬁable  permissible  error  values
p  to  ±10%  (±6  mg/dl)  in  most  sources.5,13
Subsequent  to  the  establishment  of  internal  quality
ontrol,  the  same  reagent  lot  should  be  maintained  in  bio-
hemistry  (and  hematology)  for  a  year,  in  order  to  control
erformance.14 Likewise,  variability  of  the  control  materials
rom  lot-to-lot  should  be  minimal.  Since  it  represents  a small
mount  of  observed  variation,  this  should  not  exceed  10%.15
mongst  the  community,  the  circulation  of  lyophilized  con-
rols  is  predominant,  which,  unlike  liquid  controls,  present
p
m
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igher  error  and  stability  and  lower  cost,  but  require  careful
andling  of  volumetric  material,  distilled  water  and  recon-
titution.
Within  the  community,  there  are  few  clinical  analysis  lab-
ratories  with  quality  systems  in  biochemistry.  Consistent
ith  the  evolution  of  laboratories,  most  National  hospi-
als  and  some  private  Health  Centers  in  Lima  maintain
nternal,  external  and  inter-laboratory  quality  implementa-
ion  without  a  cosmopolitan  reach  in  the  capital.  The  vast
ajority  of  new  clinical  laboratories  with  economic  limi-
ations,  interest  of  proﬁt,  or  those  which  are  unfamiliar
ith  the  clinical  impact  of  results  without  a  quality  system
nly  use  ‘‘standard  calibrator’’  controls,  usually  semiauto-
atic  biochemical  analyzers  provided  by  the  manufacturer
s  a  quality  reference  for  work  performance  evaluation  and
esult  reliability.
It is  evident  that  the  lack  of  conscience  about  this  subject
nd  the  ample  uncertainty  produced  in  the  result,  since  the
rror  is  not  quantiﬁed  or  corrected,  will  be  magniﬁed  pro-
ressively  and  become  uncontrollable.  In  this  regard,  some
f  the  most  commonly  used  reagents  in  clinical  chemistry
mongst  the  community  do  not  have  the  same  lot  inside  the
it  (in  other  words,  a  different  lot  for  the  enzymatic  reagent
nd  for  the  standard  calibrator).  Then,  how  can  the  quality
f  the  results  be  ensured  in  these  conditions?
The  objective  of  this  investigation  was  to  assess  inter-
atch  variability  in  the  determination  and  quality  control
f  glucose,  according  to  the  international  speciﬁcations
etailed  in  the  CLSI  EP-15-A3  guide.
ethod and materials
 qualitative,  analytic,  non-experimental,  prospective
ross-sectional  study  was  conducted  in  the  Clinical  Labo-
atory  Department  at  the  biochemical  area  of  the  ‘‘La  Fe’’
olyclinic  Health  Care  Center  during  January,  2015.  Glucose
nter-batch  variability  was  assessed  according  to  the  CLSI
P15-A3  guide,  highlighting  the  usefulness  of  ‘‘control  let-
ers’’  (metric  sigma,  power  control  chart  and  Normalized
PSpecs  chart).12
ample
n-probabilistic,  sampling  intentionally  by  convenience.
iochemical  analyzer
n  order  to  perform  determinations,  we  used  aURIT-810
edical  Electronic  (Guangxi,  PR  China)  semiautomatic  bio-
hemical  analyzer,  which  was  stabilized  to  220  V,  100  VA.
eagents
altek®Glucose-LS  enzymatic  liquid  reagent  (Valtek  diagno-
is,  Santiago  de  Chile,  Chile)  lot  140825,  with  a storage  range
etween  2  and  8 ◦C,  50  ml  bottle,  with  glucose  oxidase-
eroxidase  (GOD-PAP)  enzymatic  colorimetric  method,
odiﬁed  based  on  the  publication  by  Trinder  in  1969.16 First
evel  calibrator  kit  (calibrator  standard  glucose  ‘‘CS’’  (CS-
))  and  normal  ﬁxed  value  (100  ±  1  mg/dl)  of  lot  140428,  B
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Figure  1  Work  scheme  w
and  C  calibrators  (CS-B  and  CS-C)  of  lot  120912  and  131202,
respectively  (100  ±  1  mg/dl).
Control  reagent
In  order  to  perform  method  veriﬁcation,  the  kit’s  ‘‘standard
calibrators’’  were  utilized  as  controls  according  to  operative
needs.
Data  recollection  technique  and  sample  processing
According  to  the  maker’s  recommendations,  CSs  were  sta-
bilized  at  room  temperature  (room  temperature  25  ±  2 ◦C)
for  10  min  before  processing.  The  equipment  stabilized  for
10  min  before  the  analytic  runs.  A  blank  reagent  was  used
before  the  analysis  veriﬁcation  from  lot-to-lot.  In  order  to
evaluate  precision,  three  sets  of  measurements  were  made
ﬁve  days  in  a  row.  For  the  evaluation  of  veracity,  duplicates
of  the  5  days  of  the  precision  protocol  of  the  3  control  mate-
rials  for  glucose  were  necessary  (CS-A,  CS-B  and  CS-C).12
Analytic  runs  were  conducted  by  the  institution’s  personnel
under  the  work’s  protocol  speciﬁcations.17 Procedures  for
glucose  veriﬁcation  were  conducted  using  the  CLSI  EP-15-
A3  guide,  measured  in  standard  deviation  (SD)  and  variance
coefﬁcient  (%VC)  to  asses  bias  and  imprecision.  With  the
data  obtained  from  %VC,  bias  and  Tea,  the  dot  and  opera-
tive  lines  were  determined  to  evaluate  the  performance  of
the  methodology,  demonstrated  in  graphics  within  control
letters.  These  determine  the  amount  of  controls  necessary
t
1
r
f the  glucose  serum  matrix.
or  the  analytical  run,  as  well  as  the  clinical  assay  control
ules.18 The  work  outline  is  shown  in  Fig.  1.
ata  analysis  technique
ata  analysis  was  done  using  the  statistical  analyzer  IBM
PSS,  version  21  (Armonk,  USA)  and  MS  Excel  2010  (Red-
ond,  USA)  for  windows.  The  quality  matrix  was  developed
n  an  Excel  sheet  showing  SD,  %VC,  Tea,  six  sigma  and  critical
ystemic  error  (SDE  or  SE).
imitations
everal  limitations  ought  to  be  addressed  before  interpre-
ing  results.
First,  there  may  be  failures  in  the  conservation  or  sta-
ility  of  standard  calibrators,  within  domestic  distribution
y  franchises  or  the  brand’s  commercial  distributors.  These
ay  be  the  cause  for  erroneous  results.  A  second  limitation
s  the  fact  that  we  were  not  able  to  compare  the  inter-
atch  glucose  variability  results  found  in  this  study  with
hose  described  by  Valtek  reagents  for  glucose,  which  do
ot  show  signiﬁcant  systemic  differences  in  accuracy  and
mprecision  when  compared  to  other  commercial  reagents,
btained  using  the  BS  series  MINDRAY  auto-analyzer.16 A  third
imitation  is  that  the  clinical  biochemistry  laboratory  where
he  study  was  conducted  is  not  accredited  under  the  ISO
5189  norm,  but  it  does  have  the  technical  and  manage-
ial  requirements  of  the  ISO  9001  norm  implemented.  The
ourth  limitation  is  control  sera  VALTROL-N  (code  210-100)
88  
Table  1  Average  bias%,  %CV,  tea  for  glucose  with  three  CS.
CS-A  CS-B  CS-C
bias%  0  10  21
%CV 6  11  12
Teaa 10  10  10
Sigma 2  0  0.9
SE 0.35  −1.65  −0.75
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new  and  improved  calibration  method  which  improves  pre-
F
s
aa Quality requirements under CLIA’88.
nd  VALTROL-P  (code  210-110)  are  used  in  the  biochemi-
al  ﬁeld  on  a  weekly  basis.  Lastly,  not  all  linked  protocols
ere  analyzed  with  method  veriﬁcation  (linearity,  detection
imit,  reference  values,  etc.)11,17.  Despite  these  limitations,
his  research  is  the  ﬁrst  to  describe  veriﬁcation  processes,
lanning  and  quality  control  using  standard  calibrators  such
s  control  sera  in  clinical  biochemistry.
esults
f  the  conducted  research,  the  values  found  by  the  sigma
etric  calculation  were  2,  0  and  −0.9,  for  CS-A,  CS-B  and
S-C,  respectively.  These  indicate  a  very  poor  performance,
hich  cannot  be  controlled  or  maintained  within  the  appli-
ation  of  a  statistical  control  (p  <  0.05).19 (Table  1)
Sigma  metric  is  a  process  improvement  methodology.
ts  only  goal  is  to  reach  less  than  one  defect  per  million
99.9997%  successes).  Although  quality  requirements  are
ifferent  for  each  magnitude,  these  unify  with  six  sigma
n  order  to  compare  methods  with  a  single  value.20 In  this
ense,  we  are  able  to  express  values  and  know  statistical
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tandard glucose,  none  of  them  quality  stimations  (National  Test  Qual
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ontrol  strategies  based  on  sigma,  as  shown  in  Fig.  2  as  an
xample.
Other  control  letters  are  operative  speciﬁcation  graphics
OPSpecs)  and  power  control  chart.  Power  control  chart
epresent  the  most  powerful  graphic  because  of  the  vast
mount  of  data  which  can  be  obtained  from  them  during
uality  planning.  These  requires  SE  calculations,  based
n  the  method’s  maximum  permissible  error,  which  should
ot  be  more  than  the  quality  requirements  (up  to  90%
f  quality  assurance),  which  equals  the  statistical  value
f  1.65  standard  deviations.21 These  functions  present
he  information  about  the  performance  of  a  rejection
robability  graphic  control  rule  versus  the  analytic  error
easures,  as  shown  in  Fig.  3.
Every  one  of  the  cases  underwent  2  control  levels  for
very  analytical  run  (n  =  2).  Choosing  one  control  rule  for
very  analyte,  there  are  fewer  alarms  in  internal  control,
hus  freeing  the  analytical  run  with  a good  chance  of  error
etection  and  a low  probability  of  rejecting  good  runs.  Every
etter  begins  with  the  choice  of  control  rules,  according  to
ach  case  (mono-rules  or  multi-rules)  which  evaluate  and
ontrol  immeasurable  systemic  and  random  mistakes.
iscussion
erformance  characteristics  were  not  optimal  with  the  use
f  standard  calibrators  for  glucose  determination,  accord-
ng  to  the  sigma  metric  evaluation  (Table  1).  These  deﬁcient
erformances  (sigma  <  3)  suggest  a  choice  and  search  for  aision,  since  there  is  no  minimum  quality  control  under  the
tudied  conditions.  The  analysis  of  results  with  statistical
ontrol  strategy  charts  based  on  sigma  metrics  proves  that
(SE)
e)
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ccorrect planning  and  choosing  of  quality  control  rules  with  stat
analytical  quality  control  management  with  standard  cal-
ibrators  provided  by  the  manufacturer  are  not  enough  to
ensure  results  free  of  medically  signiﬁcant  errors  affect-
ing  the  health  of  the  patient.  Moreover,  statistics  show  the
speciﬁc  concentration  test  performance  in  work  conditions
inherent  to  the  mentioned  laboratory.22
The  vast  majority  of  clinical  chemistry  laboratories  in
Lima,  which  use  manual  or  semiautomatic  methodologies,
present  a  high  degree  of  inaccuracy  in  glucose  and  choles-
terol  determinations,  highlighting  not  only  the  poor  quality
of  lab  results,  but  also  the  need  for  dynamic  and  efﬁcient
controls  which  ensure  quality  in  processes.23 By  not  using
Good  Clinical  Laboratory  Practices,  the  error  is  not  quan-
tiﬁed,  thus  uncertainty  in  the  result  creates  a  bad  clinical
diagnosis.  It  is  worth  noting  that  quality  is  not  a  common
characteristic  amongst  biochemical  laboratories  in  Lima.  A
contrario  sensu, with  the  development  and  normalization  of
clinical  medicine,  doctors  and  patients  are  expecting  high
quality  results,  which  is  a  challenge  for  all  laboratories  in
the  community.
Results  provided  during  the  calibrator’s  analytical  run
should  be  truthful  and  precise  in  order  to  certify  that  routine
analytical  determinations  ensure  a  minimum  quality  and  a
correct  clinical  interpretation,  in  addition  to  being  useful
for  their  inter-laboratory  comparability.22,23
OPSpecs’  statistical  control  letters  as  well,  as  power
control  chart,  describe  the  acceptable  imprecision  and
inaccuracy  for  a  method  and  quality  control  necessary  to
supervise  performance,  as  well  as  the  test  performance
under  stable  conditions,  and  warn  if  there  are  any  changes
that  may  affect  the  report.  The  goal  is  to  obtain  <90%  prob-
ability  of  error  detection  (Ped  or  AQA)  and  less  than  5%
probability  of  false  rejection  (Pfr),  with  an  N  (amount  of
controls  being  analyzed)  as  low  as  possible  and  in  a  single
analytical  run.24 In  the  example  shown  in  Fig.  3,  none  of
the  rules  is  eligible,  with  two  controls  per  analytical  run.
Through  the  use  of  control  materials  ‘‘CS’’  and  a  proper
statistical  management,  we  are  able  to  prove  that  no  rule
or  control  is  useful  in  the  veriﬁcation  of  the  method.25,26,27
p
g
ql  control  chart.
In  the  same  manner,  the  error  in  Valtek’s  critical
lucose-LS  levels  were  estimated.  The  systemic  error  is  the
ifference  between  the  conventionally  truthful  value  and
he  median  value  of  a  number  of  determinations  which
re  experimentally  measured.  Within  this  investigation,
e  were  able  to  ﬁnd  a  0%,  10%  and  20%  of  bias  for  CS-
,  CS-B  and  CS-C,  respectively.  On  the  other  hand,  the
ystemic  error,  that  is  to  say  the  resultant  precision  of
he  approximation’s  repeated  measured  values,  were  6%,
1%  and  12%  of  CS-A,  CS-B  and  CS-C,  respectively.  These
ontinuous  quantitative  variables,  when  expressed  graph-
cally,  show  the  wide  inter-batch  variability  and  error  for
lucose.  Of  these,  only  lot  140428  (CS-A)  could  be  capa-
le  of  improving  its  performance  of  being  indispensable
or  analysis  in  the  laboratory,  in  other  words,  capa-
le  of  recognizing,  monitoring,  minimizing  and  correcting
rrors,  although  it  would  be  costly  to  maintain  it  within
uality.14,15,17
The  causes  of  this  variability  could  be  linked  to  different
otives,  which  it  is  not  an  objective  of  this  investigation  to
escribe.  But  it  is  to  consider  whether  or  not  some  factors
re  directly  interfering,  such  the  matrix  type,  signal  varia-
ion  between  equipment,  lack  of  noise  control,  CS  behavior
n  work  conditions,  measured  commutability,  transportation
nd  control  storage  and  lack  of  preventive  maintenance,
o  name  a few.  In  consequence,  full  routine  monitoring  is
neludible.
Glucose  concentration  is  very  important  for  endocri-
ologists,  diabetologists  and  diabetic  patients,  even  when
ysglycemic  or  apparently  healthy,  particularly  when  the
oncentration  is  close  to  the  upper  limit  of  the  reference
nterval  (±10%  or  6.1  mmol/L).28 The  concerning  prevalence
f  diabetes  and  prediabetes  suggests  the  immediate  prioriti-
ation  of  health  care  in  order  to  avoid  future  complications.
iagnosis  by  stimuli-response  and/or  explorations  of  the
arbohydrate  metabolism  ought  to  be  evaluated  for  all
henomena  which  may  intervene  during  every  analysis  and
enerate  non-quantiﬁable  errors,  which  will  not  ensure
uality  in  results.3,29
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onclusions
n  this  investigation,  the  measure  of  standard  glucose
alibrators  was  performed  in  order  to  prove  inter-batch
ariability  and  the  application  of  control  letters,  follow-
ng  evaluation  procedures  recommended  by  the  CLSI  EP15
uide.  Total  error  was  identiﬁed  and  quality  control  neces-
ary  to  control  the  method  performance  was  evaluated.
The  wide  inter-batch  variety  works  against  result  repro-
ucibility  and  quality,  hence  we  must  opt  for  a  different
ontrol  material  for  quality  monitoring  in  glucose-LS  deter-
ination  with  Valtek® reagents.  Quality  planning  helps
linical  analysis  laboratories  which  don’t  quantify  errors  or
uarantee  a  trustworthy  diagnosis  face  quality  challenges.
owever,  the  problem  with  variability  and  quality  control
stimations  is  that  most  laboratory  users  are  not  familiarized
ith  the  concepts  and  the  measuring  process  is  still  hier-
rchically  restrained  to  reference  methods,  which  ensure
rocess  traceability,  but  are  not  accessible  for  every  clinical
aboratory  nationwide.
It  is  not  a  problem  for  our  method  to  work  with  a  cer-
ain  degree  of  error.  The  problem  is  for  this  error  to  be
reater  than  the  maximum  permissible  amount,  according
o  the  method’s  quality  speciﬁcations.  In  this  sense,  quality
f  results  is  not  guaranteed  by  using  only  standard  calibra-
ors  provided  by  the  manufacturer;  this  evaluation  should
e  the  starting  point  to  develop  quality  processes.
Analytical  chemistry  should  not  only  equilibrate  a col-
ection  of  data  and  methods,  but  obtain  representative
amples,  optimize  methods  and  interference  management
nd  guarantee  quality  of  data.  We  hope  this  investigation
s  able  to  promote  the  use  of  optimal  control  materials  for
orrect  planning  and  quality  control  in  clinical  analysis  lab-
ratories.
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